Clinical Trial Update: Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating elagolix for safety and efficacy in women with polycystic ovary syndrome has completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycystic Ovary Syndrome

Drugs mentioned

• Elagolix (elagolix)

Snippet

Sponsor: AbbVie | Conditions: Polycystic Ovary Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2022-06-08